Guidewire Software Inc. Common Stock vs ImmunityBio Inc. Common Stock — how do they compare? Guidewire Software Inc. Common Stock trades at $165.66 (market cap $13.59B), while ImmunityBio Inc. Common Stock trades at $10.09 (market cap $10.39B). The key difference: Guidewire Software Inc. Common Stock is the larger of the two by market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, Guidewire Software Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Guidewire Software Inc. Common Stock for 0 Days and ImmunityBio Inc. Common Stock for 6 Days on average.
| GWRE | IBRX | |
|---|---|---|
Market Cap | $13.59B | $10.39B |
Volume | 838,274 | 11,509,049 |
Sector | Technology | Health |
52-Week High | $254.23 | $11.55 |
52-Week Low | $102.69 | $1.98 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $13.55B | $10.84B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ImmunityBio (IBRX) trades at $9.80, down 3.16% on the day, amid a bullish technical setup and strong analyst support. The company reported revenue growth to $166 million in 2026 but remains deeply unprofitable with a net loss of $992 million. Recent FDA approval expansion for ANKTIVA in bladder cancer and high-profile executive appointments signal operational momentum, though cash burn remains a concern with negative operating cash flow.
Outlook is cautiously optimistic given the unanimous buy ratings and regulatory milestones, but investment carries high risk due to persistent losses, heavy reliance on financing, and competitive pressures. The stock's trajectory hinges on successful commercialization and pipeline execution to achieve profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Guidewire Software Inc. develops InsuranceSuite Cloud, a software platform used by property and casualty insurers for policy administration, billing, and claims processing.
Read more on GWRE →ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →